德龙达龙通过调节SIRT1/FOXO3/PKIA轴减轻Ang II诱导的心肌缩
Cheng Chen1, Song Hu1, Heng-Jing Hu1
1Department of Cardiovascular Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Korean circulation journal
|April 24, 2024
概括
德隆达龙通过调节SIRT1/FOXO3/PKIA通路来缓解病理性心肌缩 (MH). 这项研究阐明了 dronedarone 在治疗 MH 的分子机制.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 病理性心肌缩 (MH) 损害了心脏功能.
- 德罗纳达龙在减轻心脏缩方面显示出潜在的潜力.
- MH中无人机的精确分子机制在很大程度上是未知的.
研究的目的:
- 为了阐明在心肌缩症中使用无人机的分子调节机制.
- 调查SIRT1/FOXO3/PKIA轴在无人机对 MH 的影响中的作用.
主要方法:
- 使用 ангиотензин II (Ang II) 诱导H9C2细胞缩和横向大动脉收缩 (TAC) 手术,用于大鼠MH模型.
- 评估细胞大小和基因/蛋白质表达通过水晶紫色染色,罗达胺色素染色,qRT-PCR和西部涂抹.
- 采用JASPAR和光酶测试来验证FOXO3和PKIA促进体之间的相互作用.
主要成果:
- 德罗内达龙逆转了Ang II诱导的细胞缩,并恢复了SIRT1的表达.
- SIRT1和PKIA的过度表达增强了无人机的抗缩作用.
- 通过调节SIRT1/FOXO3/PKIA信号通路,dronedarone在TAC诱导的MH大鼠中改善了心脏功能.
结论:
- 德隆达龙通过调解SIRT1/FOXO3/PKIA轴来缓解心肌缩.
- 这些发现为无人机对MH的治疗潜力提供了机械洞察力.
更多相关视频
08:05Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
2.7K
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
6.1K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
980
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
980
01:25Antihypertensive Drugs: Direct Renin Inhibitors
606
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
606
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
716
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
716
01:26Heart Failure Drugs: Inotropic Agents
574
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
621
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
621